


## Sulotroban

## Chemical Properties

CAS No. :	72131-33-0
Formula:	C16H17NO5S
Molecular Weight:	335.37
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	sulotroban is a TXA2 receptor antagonist that acts synergistically with iloprost to inhibit TXA2-dependent platelet activation.
Targets(IC50)	PPAR, Prostaglandin Receptor
In vivo	Sulotroban (5 mg/kg; i.v.; cat;) did not alter baseline vascular pressures in the cat and responses to the PG and TXA2/PGH2 precursor, arachidonic acid, were reduced. The present data show that sulotroban selectively blocks TXA2/PGH2 receptor-mediated responses in a competitive and reversible manner in the pulmonary vascular bed.[4]

## Solubility Information

Solubility	DMSO: 50 mg/mL (149.09 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2.5 mg/mL (7.45 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.9818 mL	14.9089 mL	29.8178 mL
5 mM	0.5964 mL	2.9818 mL	5.9636 mL
10 mM	0.2982 mL	1.4909 mL	2.9818 mL
50 mM	0.0596 mL	0.2982 mL	0.5964 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Stürzebecher S, et al. The PGI<sub>2</sub>-analogue iloprost and the TXA<sub>2</sub>-receptor antagonist sulotroban synergistically inhibit TXA<sub>2</sub>-dependent platelet activation. *Prostaglandins*. 1988;36(6):751-760.

Mann WA, et al. Characterization of the renal effects and renal elimination of sulotroban in the dog. *J Pharmacol Exp Ther*. 1991;259(3):1231-1240.

Fujita T, et al. Effect of selective endoperoxide/thromboxane A<sub>2</sub> receptor antagonism with sulotroban on tPA-induced thrombolysis in a rabbit model of femoral arterial thrombosis. *Fundam Clin Pharmacol*. 1989;3(6):643-653.

Nossaman BD, et al. Blockade of thromboxane/endoperoxide receptor-mediated responses in the pulmonary vascular bed of the cat by sulotroban. *Eur J Pharmacol*. 1992;213(1):1-7.

Finci L, et al. Sulotroban during and after coronary angioplasty. A double-blind, placebo controlled study. *Z Kardiol*. 1989;78 Suppl 3:50-54.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481